Therapy related myeloid neoplasm, same but different?

Authors: El Murr L; Hematology Department, Institut Gustave-Roussy, Villejuif (Île-de-France), France., Saleh K; International Department, Gustave-Roussy Cancer Campus, Villejuif, France., Pasquier F; Hematology Department, Institut Gustave-Roussy, Villejuif (Île-de-France), France; Inserm U1287, Gustave-Roussy, Université Paris-Saclay, 94805 Villejuif, France., Willekens C; Hematology Department, Institut Gustave-Roussy, Villejuif (Île-de-France), France; Inserm U1287, Gustave-Roussy, Université Paris-Saclay, 94805 Villejuif, France., Danu A; Hematology Department, Institut Gustave-Roussy, Villejuif (Île-de-France), France., Pilorge S; Hematology Department, Institut Gustave-Roussy, Villejuif (Île-de-France), France., Auger N; Medical Biology and Pathology Department, Institut Gustave-Roussy, Villejuif (Île-de-France), France., Saada V; Medical Biology and Pathology Department, Institut Gustave-Roussy, Villejuif (Île-de-France), France., Delaloge S; Medical Oncology Department, Institut Gustave-Roussy, Villejuif (Île-de-France), France., De Botton S; Hematology Department, Institut Gustave-Roussy, Villejuif (Île-de-France), France., Pagès A; Department of Biostatistics and Epidemiology, Gustave-Roussy, Villejuif, France., Micol JB; Hematology Department, Institut Gustave-Roussy, Villejuif (Île-de-France), France; Inserm U1287, Gustave-Roussy, Université Paris-Saclay, 94805 Villejuif, France. Electronic address: Jeanbaptiste.MICOL@gustaveroussy.fr.

Source: Bulletin du cancer [Bull Cancer] 2025 Dec; Vol. 112 (12), pp. 1385-1393. Date of Electronic Publication: 2025 Oct 08.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: France NLM ID: 0072416 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1769-6917 (Electronic) Linking ISSN: 00074551 NLM ISO Abbreviation: Bull Cancer Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/mortality , Myelodysplastic Syndromes*/etiology , Myelodysplastic Syndromes*/classification , Neoplasms, Second Primary*/mortality , Neoplasms, Second Primary*/etiology , Neoplasms, Second Primary*/classification , Leukemia, Myeloid, Acute*/mortality , Leukemia, Myeloid, Acute*/etiology , Leukemia, Myeloid, Acute*/classification, Humans ; Retrospective Studies ; Male ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Prognosis ; Young Adult

The discussion on the differences in immune microenvironment between low-risk and high-risk myelodysplastic syndromes and acute myeloid leukemia.

Authors: Wang Y; The Second Clinical Medical College of Lanzhou University, Lanzhou, China., Xiao X; Hematology Department, The First People's Hospital of Longnan City, Longnan, China., Zheng H; The Second Clinical Medical College of Lanzhou University, Lanzhou, China., Bai J; The Second Hospital of Lanzhou University, Lanzhou, China., Li L; The Second Clinical Medical College of Lanzhou University, Lanzhou, China.; The Second Hospital of Lanzhou University, Lanzhou, China., Zhang L; The Second Clinical Medical College of Lanzhou University, Lanzhou, China.; The Second Hospital of Lanzhou University, Lanzhou, China.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2025 Dec; Vol. 66 (13), pp. 2397-2412. Date of Electronic Publication: 2025 Sep 09.

Publication Type: Journal Article; Review

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/immunology , Myelodysplastic Syndromes*/pathology , Myelodysplastic Syndromes*/diagnosis , Myelodysplastic Syndromes*/etiology , Myelodysplastic Syndromes*/metabolism , Myelodysplastic Syndromes*/mortality , Leukemia, Myeloid, Acute*/immunology , Leukemia, Myeloid, Acute*/pathology , Leukemia, Myeloid, Acute*/etiology , Leukemia, Myeloid, Acute*/diagnosis , Leukemia, Myeloid, Acute*/metabolism , Leukemia, Myeloid, Acute*/mortality , Tumor Microenvironment*/immunology, Humans ; Prognosis ; Disease Progression ; Cytokines/metabolism ; Risk Factors

Translation of the Morphological Hallmarks of Dyserythropoiesis to Objective Morphometric Parameters by Imaging Flow Cytometry.

Authors: Despoina Violidaki DV; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Lund, Sweden.; Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden., Olof Axler OA; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Lund, Sweden., Lars Nilsson LN; Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden., Anna Porwit AP; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Lund, Sweden.; Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden., Mats Ehinger ME; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Lund, Sweden.; Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Source: International journal of laboratory hematology [Int J Lab Hematol] 2025 Dec; Vol. 47 (6), pp. 1089-1098. Date of Electronic Publication: 2025 Jul 26.

Publication Type: Journal Article

Journal Info: Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 101300213 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1751-553X (Electronic) Linking ISSN: 17515521 NLM ISO Abbreviation: Int J Lab Hematol Subsets: MEDLINE

MeSH Terms: Flow Cytometry*/methods , Myelodysplastic Syndromes*/pathology , Myelodysplastic Syndromes*/diagnosis , Erythropoiesis* , Image Cytometry*/methods, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Bone Marrow Cells/pathology ; Bone Marrow Cells/metabolism ; Aged, 80 and over ; Cell Nucleus/pathology ; Bone Marrow/pathology ; Erythroblasts/pathology

Luspatercept for the treatment of lower-risk myelodysplastic syndrome with SF3B1 mutation: a real-world single-center research in China.

Authors: Liang W; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Kang R; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Zhao Y; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Xing L; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Zhang B; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Shi Y; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Li Y; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Peng G; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Zhao X; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Liu X; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Hu J; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Hu X; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Zhou K; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Yang Y; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Xiong Y; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Li J; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Fan H; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Yang W; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Ye L; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Jing L; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Zhang L; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China., Zhang F; Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.

Source: Hematology (Amsterdam, Netherlands) [Hematology] 2025 Dec; Vol. 30 (1), pp. 2506858. Date of Electronic Publication: 2025 Jun 05.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1607-8454 (Electronic) Linking ISSN: 10245332 NLM ISO Abbreviation: Hematology Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/drug therapy , Myelodysplastic Syndromes*/genetics , RNA Splicing Factors*/genetics , Immunoglobulin Fc Fragments*/therapeutic use , Immunoglobulin Fc Fragments*/administration & dosage , Immunoglobulin Fc Fragments*/adverse effects , Recombinant Fusion Proteins*/therapeutic use , Recombinant Fusion Proteins*/adverse effects , Recombinant Fusion Proteins*/administration & dosage , Mutation* , Activin Receptors, Type II*/therapeutic use , Activin Receptors, Type II*/administration & dosage, Humans ; Male ; Female ; Middle Aged ; Aged ; China ; Retrospective Studies ; Treatment Outcome ; Phosphoproteins

Enhanced FOXO1 expression as a predictor of decitabine response and prolonged survival in high-risk myelodysplastic syndrome.

Authors: Liu H; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China., Zhang Z; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China., Huang N; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China., Xu F; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China., Zhao S; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China., Chang C; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.

Source: Hematology (Amsterdam, Netherlands) [Hematology] 2025 Dec; Vol. 30 (1), pp. 2506862. Date of Electronic Publication: 2025 May 27.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1607-8454 (Electronic) Linking ISSN: 10245332 NLM ISO Abbreviation: Hematology Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/drug therapy , Myelodysplastic Syndromes*/mortality , Myelodysplastic Syndromes*/genetics , Myelodysplastic Syndromes*/diagnosis , Forkhead Box Protein O1*/genetics , Forkhead Box Protein O1*/biosynthesis , Azacitidine*/analogs & derivatives , Azacitidine*/therapeutic use , Antimetabolites, Antineoplastic*/therapeutic use, Humans ; Decitabine/therapeutic use ; Male ; Female ; Aged ; Middle Aged ; Prognosis ; Adult ; Aged, 80 and over ; Treatment Outcome

Accelerated senescence of bone marrow erythrocyte precursors in myelodysplastic syndrome.

Authors: Liu M; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China., Yang L; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China., Liu Y; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China., Niu H; Department of Hematology, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, China., Zhang M; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China., Shao Z; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China., Xing L; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China., Wang H; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.

Source: Annals of medicine [Ann Med] 2025 Dec; Vol. 57 (1), pp. 2494676. Date of Electronic Publication: 2025 Apr 25.

Publication Type: Journal Article

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/blood , Myelodysplastic Syndromes*/complications , Myelodysplastic Syndromes*/pathology , Cellular Senescence*/physiology , Anemia*/etiology , Anemia*/blood , Erythroid Precursor Cells*/metabolism, Humans ; Male ; Female ; Aged ; Middle Aged ; Cyclin-Dependent Kinase Inhibitor p16/metabolism ; Cyclin-Dependent Kinase Inhibitor p16/genetics ; Aged, 80 and over ; Bone Marrow/pathology ; Adult ; Bone Marrow Cells ; Cyclin-Dependent Kinase Inhibitor p21/metabolism

Artificial intelligence in myeloid malignancies: Clinical applications of machine learning in myelodysplastic syndromes and acute myeloid Leukemia.

Authors: Al-Nusair J; Department of Internal Medicine, Marshall University Joan C. Edwards School of Medicine, Huntington, WV, USA. Electronic address: alnusair@marshall.edu., Lanino L; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA; Humanitas Clinical and Research Center-IRCCS, Milan, Italy. Electronic address: luca.lanino@yale.edu., Durmaz A; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: durmaza2@ccf.org., Porta MGD; Humanitas Clinical and Research Center-IRCCS, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy. Electronic address: matteo.della_porta@hunimed.eu., Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA. Electronic address: amer.zeidan@yale.edu., Kewan T; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA; Division of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address: tariq.kewan@yale.edu.

Source: Blood reviews [Blood Rev] 2025 Nov; Vol. 74, pp. 101340. Date of Electronic Publication: 2025 Oct 16.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 8708558 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1681 (Electronic) Linking ISSN: 0268960X NLM ISO Abbreviation: Blood Rev Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/diagnosis , Myelodysplastic Syndromes*/therapy , Leukemia, Myeloid, Acute*/diagnosis , Leukemia, Myeloid, Acute*/therapy , Machine Learning* , Artificial Intelligence*, Humans ; Prognosis ; Disease Management

Pathogenic mechanisms and targeted therapies for anemia in myelodysplastic syndromes.

Authors: Chang D; Department of Hematology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China., Yang L; Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, China., Zhang R; Department of Hematology, First Hospital of Shanxi Medical University, Taiyuan 030001, China. Electronic address: zhangruijuan@sxmu.edu.cn.

Source: Leukemia research [Leuk Res] 2025 Nov; Vol. 158, pp. 108099. Date of Electronic Publication: 2025 Sep 13.

Publication Type: Journal Article; Review

Journal Info: Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/complications , Myelodysplastic Syndromes*/pathology , Anemia*/etiology , Anemia*/therapy , Anemia*/pathology , Anemia*/drug therapy , Molecular Targeted Therapy*/methods, Humans

Iron chelation therapy in myelodysplastic syndromes and allogeneic hematopoietic cell transplantation, a delicate balance.

Authors: Hoff FW; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Schulz E; Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; NIH Myeloid Malignancies Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Division of Hematology, Medical University of Graz, Graz, Austria., Pavletic S; Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; NIH Myeloid Malignancies Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Mina A; Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; NIH Myeloid Malignancies Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: alain.mina@nih.gov.

Source: Blood reviews [Blood Rev] 2025 Nov; Vol. 74, pp. 101319. Date of Electronic Publication: 2025 Jun 23.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 8708558 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1681 (Electronic) Linking ISSN: 0268960X NLM ISO Abbreviation: Blood Rev Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/therapy , Myelodysplastic Syndromes*/complications , Hematopoietic Stem Cell Transplantation*/adverse effects , Hematopoietic Stem Cell Transplantation*/methods , Iron Chelating Agents*/therapeutic use , Iron Chelating Agents*/adverse effects , Iron Overload*/etiology , Iron Overload*/drug therapy , Chelation Therapy*/methods , Chelation Therapy*/adverse effects, Humans ; Transplantation, Homologous ; Iron/metabolism ; Treatment Outcome

Nutrition and Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults (Aged ≥60): A Scoping Review.

Authors: Crowder V; School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: victoria.crowder@unc.edu., Bankole AO; School of Nursing, Duke University, Durham, North Carolina., Conklin JL; Health Sciences Library, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Sawyer AS; Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Holliday AM; Atrium Health, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina., Fogle R; North Carolina Cancer Hospital, Chapel Hill, North Carolina., Coombs LA; School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Richardson DR; Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Batchelor M; The George Washington University School of Nursing, Washington, District of Columbia., Beeber A; Johns Hopkins University School of Nursing, Baltimore, Maryland., Schwartz T; School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Bryant AL; School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Source: Journal of the Academy of Nutrition and Dietetics [J Acad Nutr Diet] 2025 Nov; Vol. 125 (11), pp. 1678-1717.e4. Date of Electronic Publication: 2025 Jun 20.

Publication Type: Journal Article; Scoping Review

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101573920 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-2672 (Print) Linking ISSN: 22122672 NLM ISO Abbreviation: J Acad Nutr Diet Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/psychology , Myelodysplastic Syndromes*/complications , Myelodysplastic Syndromes*/physiopathology , Leukemia, Myeloid, Acute*/complications , Leukemia, Myeloid, Acute*/psychology , Leukemia, Myeloid, Acute*/physiopathology , Nutritional Status*, Humans ; Aged ; Quality of Life ; Male ; Female ; Middle Aged ; Aged, 80 and over ; Malnutrition

Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence.

Authors: Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA., Zhao R; Taiho Oncology, Inc, Princeton, NJ, USA., Epstein RS; Epstein Health, Woodcliff Lake, NJ, USA., Salimi T; Taiho Oncology, Inc, Princeton, NJ, USA.

Source: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2025 Nov; Vol. 25 (11), pp. 1243-1250. Date of Electronic Publication: 2025 Aug 09.

Publication Type: Journal Article; Review

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/drug therapy , Myelodysplastic Syndromes*/economics , Myelodysplastic Syndromes*/pathology , Decitabine*/administration & dosage , Decitabine*/economics , Uridine*/analogs & derivatives , Uridine*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/economics, Humans ; Quality of Life ; Administration, Oral ; Patient-Centered Care ; Age Factors ; Health Care Costs ; Aged ; Drug Combinations

Burden of myelodysplastic syndromes: a systematic literature review of economic burden.

Authors: Tse P; Department of Health Research, Methods, Evidence, and Impact, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada., Xie S; School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China., Yan J; Department of Health Research, Methods, Evidence, and Impact, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada., Humphries B; Department of Health Research, Methods, Evidence, and Impact, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada., Xie F; Department of Health Research, Methods, Evidence, and Impact, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada. fengxie@mcmaster.ca.

Source: The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2025 Nov; Vol. 26 (8), pp. 1469-1485. Date of Electronic Publication: 2025 Apr 23.

Publication Type: Journal Article; Systematic Review

Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101134867 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-7601 (Electronic) Linking ISSN: 16187598 NLM ISO Abbreviation: Eur J Health Econ Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/economics , Myelodysplastic Syndromes*/therapy , Cost of Illness* , Health Care Costs*/statistics & numerical data, Humans ; United States

Low serum complement C3 levels are associated with adverse clinical outcomes in myelodysplastic syndromes.

Authors: Zou D; Laboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, China., Ying H; Department of Laboratory Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, China., Yong L; Laboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, China., Cao J; Laboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, China., Liu Y; Department of Laboratory Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, China., Ouyang G; Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China., Mu Q; Laboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, China. Electronic address: muqitian@163.com.

Source: Leukemia research [Leuk Res] 2025 Nov; Vol. 158, pp. 108116. Date of Electronic Publication: 2025 Oct 03.

Publication Type: Journal Article

Journal Info: Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/blood , Myelodysplastic Syndromes*/mortality , Complement C3*/metabolism , Complement C3*/analysis, Humans ; Male ; Female ; Aged ; Middle Aged ; Prognosis ; Aged, 80 and over ; Retrospective Studies ; Adult

Impact of inflammatory cytokine polymorphisms on the progression of myelodysplastic syndromes.

Authors: Gotoh N; Department of Laboratory Science, Graduate School of Health Sciences, Gunma University, Maebashi, 371-8514, Gunma, Japan., Munkh-Erdene T; Department of Laboratory Science, Graduate School of Health Sciences, Gunma University, Maebashi, 371-8514, Gunma, Japan., Hayashi A; Department of Laboratory Science, Graduate School of Health Sciences, Gunma University, Maebashi, 371-8514, Gunma, Japan., Kasamatsu T; Faculty of Medical Technology and Clinical Engineering, Gunma University of Health and Welfare, Maebashi, Japan., Kitamura M; Department of Laboratory Science, Graduate School of Health Sciences, Gunma University, Maebashi, 371-8514, Gunma, Japan., Kojima A; Department of Laboratory Science, Graduate School of Health Sciences, Gunma University, Maebashi, 371-8514, Gunma, Japan., Okawa T; Department of Laboratory Science, Graduate School of Health Sciences, Gunma University, Maebashi, 371-8514, Gunma, Japan., Oda T; Laboratory of Mucosal Ecosystem Design, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma, Japan., Miyauchi E; Laboratory of Mucosal Ecosystem Design, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma, Japan., Sasaki N; Laboratory of Mucosal Ecosystem Design, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma, Japan., Matsumura I; Department of Hematology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan., Matsumoto A; Department of Hematology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan., Takei H; Department of Hematology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan., Kobayashi N; Department of Hematology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan., Miyazawa Y; Department of Hematology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan., Ogawa Y; Division of Blood Transfusion Service, Gunma University Hospital, Maebashi, Gunma, Japan., Handa H; Department of Hematology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan., Saitoh T; Department of Laboratory Science, Graduate School of Health Sciences, Gunma University, Maebashi, 371-8514, Gunma, Japan. tsaitoh@gunma-u.ac.jp.

Source: Annals of hematology [Ann Hematol] 2025 Oct; Vol. 104 (10), pp. 5111-5123. Date of Electronic Publication: 2025 Sep 19.

Publication Type: Journal Article

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/genetics , Myelodysplastic Syndromes*/pathology , Myelodysplastic Syndromes*/diagnosis , Interleukin-1beta*/genetics , Polymorphism, Single Nucleotide* , Interferon-gamma*/genetics , Tumor Necrosis Factor-alpha*/genetics , Cytokines*/genetics, Humans ; Male ; Female ; Aged ; Middle Aged ; Disease Progression ; Aged, 80 and over ; Adult

Characteristics and prognostic implications of TP53 mutations in Chinese patients with myelodysplastic syndromes.

Authors: Huang N; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China., Chang C; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China., Wu L; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China., He Q; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China., Zhang Z; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China., Li X; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China., Xu F; Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Source: British journal of haematology [Br J Haematol] 2025 Oct; Vol. 207 (4), pp. 1397-1407. Date of Electronic Publication: 2025 Aug 04.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

MeSH Terms: Mutation* , Myelodysplastic Syndromes*/genetics , Myelodysplastic Syndromes*/mortality , Myelodysplastic Syndromes*/diagnosis , Tumor Suppressor Protein p53*/genetics , East Asian People*/ethnology , East Asian People*/genetics, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; China/epidemiology ; China/ethnology ; Disease Progression ; Leukemia, Myeloid, Acute/genetics ; Prognosis ; RNA Splicing Factors/genetics

Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims.

Authors: Komrokji RS; Moffitt Cancer Center, Tampa, FL. Electronic address: rami.komrokji@moffitt.org., Supina D; Geron Corporation, Foster City, CA., Navada S; Geron Corporation, Foster City, CA., Potluri R; Putnam Inizio Advisory, New York, NY., Tyagi R; Putnam Inizio Advisory, Gurugram, India., Werwath T; Putnam Inizio Advisory, New York, NY., Xie Z; Moffitt Cancer Center, Tampa, FL., Padron E; Moffitt Cancer Center, Tampa, FL., Sallman DA; Moffitt Cancer Center, Tampa, FL.

Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2025 Oct; Vol. 25 (10), pp. e740-e749. Date of Electronic Publication: 2025 Apr 19.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/therapy , Myelodysplastic Syndromes*/mortality , Erythrocyte Transfusion*/statistics & numerical data, Humans ; Male ; Female ; Aged ; United States/epidemiology ; Middle Aged ; Aged, 80 and over ; Adult

Myeloid Neoplasms With Oligomonocytosis Exhibit Heterogenous Pathologic and Genetic Features.

Authors: Baloda V; Department of Pathology, UPMC, Pittsburgh, Pennsylvania; Now with Memorial Sloan Kettering Cancer Center, New York, New York., Al Amri R; Department of Pathology, UPMC, Pittsburgh, Pennsylvania; Now with National Guard Health Affairs, Riyadh, Saudi Arabia., Patwardhan PP; Department of Pathology, UPMC, Pittsburgh, Pennsylvania., Monaghan SA; Department of Pathology, UPMC, Pittsburgh, Pennsylvania; Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania., Moore EM; Department of Pathology, UPMC, Pittsburgh, Pennsylvania; Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania., Rea B; Department of Pathology, UPMC, Pittsburgh, Pennsylvania; Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania., Djokic M; NeoGenomics Laboratories, Fort Myers, Florida., Aggarwal N; Department of Pathology, UPMC, Pittsburgh, Pennsylvania; Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania., Bullock GC; Department of Pathology, University of Iowa, Iowa City, Iowa., Liu YC; St. Jude Children's Research Hospital, Memphis, Tennessee., Yatsenko S; Department of Pathology, Stanford Medicine, Palo Alto, California., Bailey NG; Department of Pathology, UPMC, Pittsburgh, Pennsylvania; Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania; Now with Mayo Clinic, Rochester, Minnesota. Electronic address: bailey.nathanael@mayo.edu.

Source: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2025 Oct; Vol. 38 (10), pp. 100823. Date of Electronic Publication: 2025 Jun 18.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 8806605 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-0285 (Electronic) Linking ISSN: 08933952 NLM ISO Abbreviation: Mod Pathol Subsets: MEDLINE

MeSH Terms: Leukemia, Myelomonocytic, Chronic*/pathology , Leukemia, Myelomonocytic, Chronic*/genetics , Leukemia, Myelomonocytic, Chronic*/classification , Myelodysplastic Syndromes*/genetics , Myelodysplastic Syndromes*/pathology , Myelodysplastic Syndromes*/classification, Humans ; Male ; Female ; Aged ; Middle Aged ; Monocytes/pathology ; Aged, 80 and over ; Leukocyte Count ; Adult

TP-0903 Suppresses Aurora A-PLK1 Signaling to Inhibit Proliferation of a Myelodysplastic Syndrome-Derived Cell Line.

Authors: Kimura-Hyoda T; Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Ryu M; Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Yuta R; Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Fukumoto S; Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Hosokawa K; Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Yao H; Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Yasuda Y; Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Miura K; Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan., Tohyama K; Department of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan., Arai F; Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Uchiumi T; Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Source: Cancer science [Cancer Sci] 2025 Oct; Vol. 116 (10), pp. 2831-2845. Date of Electronic Publication: 2025 Jul 28.

Publication Type: Journal Article

Journal Info: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/metabolism , Myelodysplastic Syndromes*/drug therapy , Myelodysplastic Syndromes*/pathology , Myelodysplastic Syndromes*/genetics , Proto-Oncogene Proteins*/metabolism , Cell Cycle Proteins*/metabolism , Protein Serine-Threonine Kinases*/metabolism , Aurora Kinase A*/metabolism , Aurora Kinase A*/antagonists & inhibitors, Humans ; Cell Proliferation/drug effects ; Signal Transduction/drug effects ; Polo-Like Kinase 1 ; Cell Line, Tumor ; Apoptosis/drug effects ; Phosphorylation/drug effects

Management of iron overload in adult myelodysplastic syndrome.

Authors: Leitch HA; Division of Hematology, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada., Buckstein R; Division of Hematology, Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Source: Hematology. American Society of Hematology. Education Program [Hematology Am Soc Hematol Educ Program] 2025 Dec 05; Vol. 2025 (1), pp. 87-95.

Publication Type: Journal Article; Review

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 100890099 Publication Model: Print Cited Medium: Internet ISSN: 1520-4383 (Electronic) Linking ISSN: 15204383 NLM ISO Abbreviation: Hematology Am Soc Hematol Educ Program Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/therapy , Myelodysplastic Syndromes*/complications , Myelodysplastic Syndromes*/metabolism , Iron Overload*/therapy , Iron Overload*/etiology, Humans ; Adult ; Iron/metabolism ; Erythrocyte Transfusion ; Iron Chelating Agents/therapeutic use

Updates in low/intermediate-risk MDS.

Authors: Carraway HE; Cleveland Clinic, Leukemia Program, Taussig Cancer Institute, Cleveland, OH.

Source: Hematology. American Society of Hematology. Education Program [Hematology Am Soc Hematol Educ Program] 2025 Dec 05; Vol. 2025 (1), pp. 699-708.

Publication Type: Journal Article; Review

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 100890099 Publication Model: Print Cited Medium: Internet ISSN: 1520-4383 (Electronic) Linking ISSN: 15204383 NLM ISO Abbreviation: Hematology Am Soc Hematol Educ Program Subsets: MEDLINE

MeSH Terms: Myelodysplastic Syndromes*/therapy , Myelodysplastic Syndromes*/diagnosis , Myelodysplastic Syndromes*/genetics , Myelodysplastic Syndromes*/drug therapy, Humans ; Lenalidomide/therapeutic use ; Receptors, Fc/therapeutic use ; Hematinics/therapeutic use ; Activin Receptors, Type II/therapeutic use ; Immunoglobulin Fc Fragments ; Recombinant Fusion Proteins